Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Amy J. Davidoff, PhD, Jessica B Long, MPH, Natalia Neparidze, MD, Jan Philipp Bewersdorf, MD, Rory M. Shallis, MD, Nikolai A. Podoltsev, MD PhD, Rong Wang, PhD, Steven D. Gore, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD MPH

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140728

Published: 2020

Journal Articles

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Amer M. Zeidan, MBBS, MHS, Victoria Wang, Jerald P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD, Elad Sharon, MD MPH, Steven D. Gore, MD, Selina M. Luger, MD FRCPC, Mark Litzow, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137734

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Gregory A. Abel, MD MPH, Donnie Hebert, PhD, Cecilia Lee, DrPH, RN, James M. Foran, MD, Steven D. Gore, MD, Wael Saber, MD MS, Dana Elise Rollison, PhD, Eric Padron, MD, Steffanie H. Wilson, PhD, Jason Thompson, MS, MBA, Myron Waclawiw, PhD, Nancy L. DiFronzo, PhD, Mikkael A. Sekeres

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136992

Published: 2020

Journal Articles

Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia

Jan Philipp Bewersdorf, MD, Stephanie Prozora, BS, MD, Rong Wang, PhD, Nikolai A. Podoltsev, MD PhD, Rory M. Shallis, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Xiaomei Ma, PhD, Steven D. Gore, MD, Amer M. Zeidan, MBBS, MHS, Amy J. Davidoff, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-136983

Published: 2020

Journal Articles

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

Amer M. Zeidan, MBBS, MHS, Rong Wang, PhD, Xiaoyi Wang, MD MPH, Rory M Shallis, MD, Nikolai A. Podoltsev, MD PhD, Jan Philipp Bewersdorf, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Smith Giri, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 646.

https://doi.org/10.1182/blood-2019-127398

Published: 2019

Journal Articles

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

Rong Wang, PhD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD, Nikolai A. Podoltsev, MD PhD

Blood (2019) 134 (Supplement_1): 330.

https://doi.org/10.1182/blood-2019-127568

Published: 2019

Journal Articles

Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study

Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Xiaoyi Wang, MD MPH, Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Smith Giri, MBBS, MHS, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J Davidoff, PhD MS, Rong Wang, PhD

Blood (2019) 134 (Supplement_1): 116.

https://doi.org/10.1182/blood-2019-126643

Published: 2019

Journal Articles

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Stephen A Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R Mohan, MD MSCI, Amer M. Zeidan, MBBS, MHS, Merrida A Childress, PhD, Gregory D Ayers, MS, Michael T Byrne, DO, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 180.

https://doi.org/10.1182/blood-2019-131520

Published: 2019

Journal Articles

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Lohith Gowda, MD MRCP, Karl Hager, PhD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5173.

https://doi.org/10.1182/blood-2019-127162

Published: 2019

Journal Articles

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Autumn Diadamo, BS, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5174.

https://doi.org/10.1182/blood-2019-127277

Published: 2019

Journal Articles

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study

Blood (2019) 134 (Supplement_1): 4271.

https://doi.org/10.1182/blood-2019-126978

Published: 2019

Journal Articles

The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia

Nikolai A. Podoltsev, MD PhD, Rong Wang, PhD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 2125.

https://doi.org/10.1182/blood-2019-127563

Published: 2019

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study

Ling Zhang, MD, Donald M Stablein, PhD, Pearlie Epling-Burnette, PhD PharmD, Alexandra M. Harrington, MDMT(ASCP), Lynn C. Moscinski, MD, Steven Kroft, MD, Amy E. DeZern, MD, Tareq Al Baghdadi, MD, Jane Jijun Liu, MD, Matthew J. Walter, MD, Rafael Bejar, MD PhD, Edward J. Gorak, DO, MBA, MS, Rami S. Komrokji, MD, Gregory A. Abel, MD MPH, Bart L Scott, MD, Steven D. Gore, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 4370.

https://doi.org/10.1182/blood-2018-99-116629

Published: 2018

Journal Articles

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey

Alexander B Pine, MD PhD, Nora B Chokr, MD, Maximilian Stahl, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Mark R. Litzow, MD, Selina Luger, MD, Richard M. Stone, MD, Peter L Greenberg, MD, Rafael Bejar, MD PhD, Steven D. Gore, MD, Amer M. Zeidan, MBBS, MHS

Blood (2018) 132 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2018-99-113888

Published: 2018

Journal Articles

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Amer M. Zeidan, MBBS, MHS, Weiwei Zhu, MPH, Rong Wang, PhD, Maximilian Stahl, MD, Scott F Huntington, MDMPH, Smith Giri, MBBS, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, MD PhD, Amy J. Davidoff, PhD MS

Blood (2018) 132 (Supplement 1): 838.

https://doi.org/10.1182/blood-2018-99-116497

Published: 2018

Journal Articles

Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis

Amer M. Zeidan, MBBS, MHS, Xin Hu, MS, Weiwei Zhu, MPH, Maximilian Stahl, MD, Smith Giri, MBBS, Scott F Huntington, MDMPH, Rong Wang, PhD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, MD PhD, Amy J. Davidoff, PhD MS

Blood (2018) 132 (Supplement 1): 370.

https://doi.org/10.1182/blood-2018-99-111052

Published: 2018

Journal Articles

Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States

Smith Giri, MBBS, Weiwei Zhu, MPH, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J. Davidoff, PhD MS, Scott F Huntington, MDMPH

Blood (2018) 132 (Supplement 1): 978.

https://doi.org/10.1182/blood-2018-99-119791

Published: 2018

NARROW

Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study

The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis

Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only